Effect of telmisartan in treating metabolic syndrome
Li Bo
Liu Weiwei
Abstract：Objective To evaluate the effect telmisartan in treating metabolic syndrome.Methods Totally 80 metabolic syndrome patients from September 2011 to September 2012 at Haiyang Hospital of the Affiliated Hospital,Qingdao University Medical College were divided into life style-intervention group (n =40) and telmisartan group with telmisartan 80 mg/d (n =40).The patients in life style-intervention group received diet control ± physical exercise and the patients in telmisartan group had extra telmisartan (80 mg/d).The blood pressure,blood glucose,fasting insulin (FINS),insulin resistance index (HOMA-IR),blood lipid and high-sensitivity C-reactive protein (hs-CRP) were observed before and 6-month after treatment.Results In telmisartan group,6 month after treatment,systolic blood pressure (SBP),diastolic blood pressure (DBP),fasting plasma glucose (FPG),2 h postprandial blood glucose (2 hPG),FINS,HOMA-IR and hs-CRP were significantly decreased compared with those before treatment [(125 ± 12) mmHg vs (144 ± 12) mmHg,(81 ± 8) mmHg vs (92 ± 10) mmHg,(5.1 ± 1.7) mmol/L vs (6.3 ± 2.0) mmol/L,(7.4 ± 1.6) mmol/L vs (9.5 ± 2.8) mmol/L,(7.7±1.7)mU/L vs (10.6±2.7) mU/L,(1.7±0.5) vs (2.7±0.7),(2.7 ±0.6)mg/L vs (5.4± 1.5) mg/L] (all P ＜ 0.01),but the triglyceride (TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were not significantly changed after treatment [(2.3±0.5) mmol/L vs (2.5 ±0.6) mmol/L,(4.9 ±0.8) mmol/L vs (5.2 ±0.9) mmol/L,(3.2 ± 0.5) mmol/L vs (3.4 ± 0.5) mmol/L,(1.1 ± 0.3) mmol/L vs (1.0 ± 0.3) mmol/L,all P ＞ 0.05].In life style-intervention group,blood pressure,glucose,TG,TC,LDL-C and hs-CRP were not significantly improved (all P ＞0.05) after 6 months.SBP,DBP,FPG,2hPG,FINS,HOMA-IR and hs-CRP in telmisartan group after 6 months of treatment were significantly lower than those in life style-intervention group [(138 ± 13) mmHg,(89±8) mmHg,(6.0±2.0) mmol/L,(9.0±2.2) mmol/L,(9.9 ±2.4) mU/L,(2.5 ±0.5),(5.0± 1.4) mg/L] (all P ＜0.05).No serious adverse reactions occurred in telmisartan group.Conclusion Telmisartan can not only improve the blood pressure,metabolic disorders of blood glucose,lipid and insulin resistance,but also can safely reduce the level of serum hs-CRP in patients of metabolic syndrome,without serious adverse reactions and the safety is fine.
Keywords：TelmisartanMetabolic syndromeInsulin resistanceHigh-sensitivity C-reactive protein
Publication Date：2015-09-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1318-1321 )